Table 4 The information of the 19 KEGG pathways obtained using the DAVID database
ID | Term | Gene Ratio | P value | Count |
|---|---|---|---|---|
hsa05200 | Pathways in cancer | 71.43% | 2.61E-09 | 10 |
hsa05207 | Chemical carcinogenesis—receptor activation | 50.00% | 1.87E-07 | 7 |
hsa05206 | MicroRNAs in cancer | 42.86% | 4.09E-05 | 6 |
hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 35.71% | 1.15E-04 | 5 |
hsa05203 | Viral carcinogenesis | 35.71% | 1.39E-04 | 5 |
hsa05215 | Prostate cancer | 28.57% | 2.98E-04 | 4 |
hsa04066 | HIF-1 signaling pathway | 28.57% | 4.20E-04 | 4 |
hsa04915 | Estrogen signaling pathway | 28.57% | 8.37E-04 | 4 |
hsa05165 | Human papillomavirus infection | 35.71% | 8.85E-04 | 5 |
hsa05205 | Proteoglycans in cancer | 28.57% | 0.00262 | 4 |
hsa05163 | Human cytomegalovirus infection | 28.57% | 0.003413 | 4 |
hsa05211 | Renal cell carcinoma | 21.43% | 0.0041 | 3 |
hsa05212 | Pancreatic cancer | 21.43% | 0.004953 | 3 |
hsa01521 | EGFR tyrosine kinase inhibitor resistance | 21.43% | 0.005342 | 3 |
hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 21.43% | 0.006737 | 3 |
hsa04657 | IL-17 signaling pathway | 21.43% | 0.00749 | 3 |
hsa01522 | Endocrine resistance | 21.43% | 0.008119 | 3 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 21.43% | 0.008442 | 3 |
hsa04659 | Th17 cell differentiation | 21.43% | 0.009792 | 3 |